Notably, escitalopram is reported to enhance synaptic plasticity within three to five weeks in healthy individuals (44), positioning it as a promising candidate for improving insulin sensitivity while and simultaneously addressing the dual challenges posed by T2DM and MDD. This evidence concerns the gene INS and major depressive disorder.